普卡那肽治疗便秘型肠易激综合征的疗效、安全性与耐受性:两项3期随机临床试验结果
两项相同的3期随机双盲安慰剂对照试验评估普卡那肽(3或6 mg)治疗符合Rome III标准的便秘型肠易激综合征(IBS-C)成人患者12周的疗效与安全性。共随机2189例,主要终点总体应答率在两项研究中各剂量均显著高于安慰剂,最常见不良事件为腹泻,因腹泻停药少见。
要点
- 研究1总体应答率:普卡那肽3 mg 30.2%、6 mg 29.5% vs 安慰剂17.8%(各剂量vs安慰剂P<0.001)。
- 研究2总体应答率:普卡那肽3 mg 21.5%(P=0.009)、6 mg 24.0%(P<0.001) vs 安慰剂14.2%。
- 最常见不良事件为腹泻(3 mg 4.3%、6 mg 4.0%、安慰剂1.0%),因腹泻停药少见(1.2%、1.4%、0)。
核心结论
- 普卡那肽显著改善IBS-C患者的腹痛和便秘症状,相关副作用轻微且耐受性高。
研究设计与样本
- 两项相同设计的3期随机双盲安慰剂对照试验,成人IBS-C患者按1:1:1随机接受安慰剂或普卡那肽3 mg或6 mg治疗12周。
- 两项研究共随机2189例,1879例完成研究。
主要发现
- 研究1总体应答率:普卡那肽3 mg 30.2%、6 mg 29.5% vs 安慰剂17.8%(各剂量vs安慰剂P<0.001)。
- 研究2总体应答率:普卡那肽3 mg 21.5%(P=0.009)、6 mg 24.0%(P<0.001) vs 安慰剂14.2%。
- 持续疗效应答率(总体应答且12周治疗期最后4周中至少2周为每周应答)在两项研究中各剂量均显著高于安慰剂。
- 所有次要终点(排便频率/性状、排便费力、腹部症状)较安慰剂显示统计学显著改善。
- 最常见不良事件为腹泻(3 mg 4.3%、6 mg 4.0%、安慰剂1.0%),因腹泻停药少见(3 mg 1.2%、6 mg 1.4%、安慰剂0)。
关键数值与推荐
- 主要疗效终点为总体应答率:同一周内最严重腹痛较基线降低≥30%且每周完全自发排便(CSBM)较基线增加≥1次,12周治疗中≥6周满足。
临床怎么用
- 普卡那肽3 mg或6 mg每日一次治疗12周可显著改善IBS-C患者的腹痛和便秘症状,常见不良事件为腹泻。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). METHODS: Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline in the same week for ≥6 of 12 treatment weeks). Safety was assessed by adverse events (AEs). RESULTS: Overall, 2189 individuals were randomized across the two studies and 1879 completed the studies. Demographic and baseline characteristics were similar across treatment groups and between studies. The percentage of overall responders in Study 1 was 30.2% and 29.5% for plecanatide 3 and 6 mg, respectively, vs. 17.8% placebo (P < 0.001 for each dose vs. placebo), and in Study 2 was 21.5% (P = 0.009) and 24.0% (P < 0.001) for plecanatide 3 and 6 mg, respectively, compared to 14.2% for placebo. The percentage of sustained efficacy responders (overall responders plus weekly responders for ≥2 of last 4 weeks of the 12-week treatment period) was significantly greater for both doses of plecanatide vs. placebo across both studies. All secondary end points (stool frequency/consistency, straining, abdominal symptoms) showed statistically significant improvements compared with placebo. The most common AE was diarrhea (3 mg, 4.3%; 6 mg, 4.0%; placebo, 1.0%). Discontinuation due to diarrhea was infrequent (3 mg, 1.2%; 6 mg, 1.4%; placebo, 0). CONCLUSIONS: Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS-C with minimal associated side effects and high levels of tolerability.
引用
- Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018. PMID: 29545635. doi:10.1038/s41395-018-0026-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。